A Preliminary Trial: Double-Blind Comparison of Nefazodone, Bupropion-SR, and Placebo in the Treatment of Cannabis Dependence.
Saved in:
| Title: | A Preliminary Trial: Double-Blind Comparison of Nefazodone, Bupropion-SR, and Placebo in the Treatment of Cannabis Dependence. |
|---|---|
| Authors: | Carpenter, Kenneth M. (AUTHOR), McDowell, David (AUTHOR), Brooks, Daniel J. (AUTHOR), Cheng, Wendy Y. (AUTHOR), Levin, Frances R. (AUTHOR) |
| Source: | American Journal on Addictions. Jan/Feb2009, Vol. 18 Issue 1, p53-64. 12p. 1 Diagram, 4 Charts. |
| Subjects: | Antidepressants, Clinical trials, Marijuana abuse, Placebos, Drug withdrawal symptoms, Cannabis (Genus), Treatment of drug addiction, Clinical medicine research, Smokable plants |
| Abstract: | The present study investigated the efficacy of nefazodone and bupropion-sustained release for treating cannabis dependence. A double-blind, placebo-controlled, piggy back design was employed to assess if nefazodone and bupropion-sustained release increased the probability of abstinence from cannabis and reduced the severity of cannabis dependence and cannabis withdrawal symptoms during a 13-week outpatient treatment program. One-hundred and six participants (Mean = 32 years; females n = 25) were randomized to one of three medication conditions (nefazodone, bupropion-sustained release, or placebo) and participated in a weekly, individually based coping skills therapy program. Results indicated an increased probability of achieving abstinence over the course of treatment and a decrease in the severity of cannabis dependence and the withdrawal symptom of irritability. There were no significant effects demonstrated for nefazodone and bupropion-sustained release on cannabis use or cannabis withdrawal symptoms. The results indicate nefazodone and bupropion-sustained release may have limited efficacy in treating cannabis dependence. [ABSTRACT FROM AUTHOR] |
| Copyright of American Journal on Addictions is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | The present study investigated the efficacy of nefazodone and bupropion-sustained release for treating cannabis dependence. A double-blind, placebo-controlled, piggy back design was employed to assess if nefazodone and bupropion-sustained release increased the probability of abstinence from cannabis and reduced the severity of cannabis dependence and cannabis withdrawal symptoms during a 13-week outpatient treatment program. One-hundred and six participants (Mean = 32 years; females n = 25) were randomized to one of three medication conditions (nefazodone, bupropion-sustained release, or placebo) and participated in a weekly, individually based coping skills therapy program. Results indicated an increased probability of achieving abstinence over the course of treatment and a decrease in the severity of cannabis dependence and the withdrawal symptom of irritability. There were no significant effects demonstrated for nefazodone and bupropion-sustained release on cannabis use or cannabis withdrawal symptoms. The results indicate nefazodone and bupropion-sustained release may have limited efficacy in treating cannabis dependence. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 10550496 |
| DOI: | 10.1080/10550490802408936 |
